Innate Pharma Stock Market Value
| IPHA Stock | USD 1.54 0.04 2.67% |
| Symbol | Innate |
Innate Pharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share 0.419 | Quarterly Revenue Growth (0.69) | Return On Assets (0.14) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Innate Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Innate Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Innate Pharma.
| 06/03/2024 |
| 11/30/2024 |
If you would invest 0.00 in Innate Pharma on June 3, 2024 and sell it all today you would earn a total of 0.00 from holding Innate Pharma or generate 0.0% return on investment in Innate Pharma over 180 days. Innate Pharma is related to or competes with Eliem Therapeutics, HCW Biologics, Inhibrx, Anebulo Pharmaceuticals, Shattuck Labs, Champions Oncology, and Century Therapeutics. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the trea... More
Innate Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Innate Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Innate Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 29.5 | |||
| Value At Risk | (10.68) | |||
| Potential Upside | 7.96 |
Innate Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innate Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Innate Pharma's standard deviation. In reality, there are many statistical measures that can use Innate Pharma historical prices to predict the future Innate Pharma's volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (1.31) | |||
| Treynor Ratio | (0.31) |
Innate Pharma Backtested Returns
Innate Pharma holds Efficiency (Sharpe) Ratio of -0.0978, which attests that the entity had a -0.0978% return per unit of risk over the last 3 months. Innate Pharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Innate Pharma's Standard Deviation of 5.09, risk adjusted performance of (0.06), and Market Risk Adjusted Performance of (0.30) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.47, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Innate Pharma will likely underperform. At this point, Innate Pharma has a negative expected return of -0.49%. Please make sure to check out Innate Pharma's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Innate Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.14 |
Insignificant predictability
Innate Pharma has insignificant predictability. Overlapping area represents the amount of predictability between Innate Pharma time series from 3rd of June 2024 to 1st of September 2024 and 1st of September 2024 to 30th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Innate Pharma price movement. The serial correlation of 0.14 indicates that less than 14.0% of current Innate Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.14 | |
| Spearman Rank Test | -0.12 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Innate Pharma lagged returns against current returns
Autocorrelation, which is Innate Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Innate Pharma's stock expected returns. We can calculate the autocorrelation of Innate Pharma returns to help us make a trade decision. For example, suppose you find that Innate Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Innate Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Innate Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Innate Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Innate Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
Innate Pharma Lagged Returns
When evaluating Innate Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Innate Pharma stock have on its future price. Innate Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Innate Pharma autocorrelation shows the relationship between Innate Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in Innate Pharma.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Innate Pharma Correlation, Innate Pharma Volatility and Innate Pharma Alpha and Beta module to complement your research on Innate Pharma. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Innate Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.